Intriguingly, in POLE mutated lung adenocarcinomas the median TMB was increased by 1.6-fold per Mb (p = 0.026), and both PD-L1 expression and CD8+ tumor infiltrating lymphocytes were higher in this subgroup of NSCLC patients, suggesting POLE mutation as a candidate biomarker to predict the response to immunotherapy [127]. This evidence concerns the gene CD8A and neoplasm.